Cited by 129COVID-19 and healthcare impactsCOVID-19 Clinical Research StudiesCOVID-19 epidemiological studies

The DOI matches its Crossref record; 61 of the 64 references it cites were found in a registry or an index.

Cancer associates with risk and severe events of COVID ‐19: A systematic review and meta‐analysis

Open access

Abstract

Evidence is mounting to indicate that cancer patients may have more likelihood of having coronavirus disease 2019 (COVID-19) but lack consistency. A robust estimate is urgently needed to convey appropriate information to the society and the public, in the time of ongoing COVID-19 pandemic. We performed a systematic review and meta-analysis through a comprehensive literature search in major databases in English and Chinese, and two investigators conducted publication selection and data extraction independently. A meta-analysis was used to obtain estimates of pooled prevalence of cancer in patients with COVID-19 and determine the association of cancer with severe events, after assessment of potential heterogeneity, publication bias, and correction for the estimates when necessary. Total 38 studies comprising 7094 patients with COVID-9 were included; the pooled prevalence of cancer was estimated at 2.3% (95% confidence limit [CL] [0.018, 0.029]; P < .001) overall and 3.2% (95% CL [0.023, 0.041]; P < .001) in Hubei province; the corresponding estimates were 1.4% and 1.9% after correction for publication bias; cancer was significantly associated with the events of severe cases (odds ratio [OR] = 2.20, 95% CL [1.53, 3.17]; P < .001) and death (OR = 2.97, 95% CL [1.48, 5.96]; P = .002) in patients with COVID-19, there was no significant heterogeneity and a minimal publication bias. We conclude that cancer comorbidity is associated with the risk and severe events of COVID-19; special measures should be taken for individuals with cancer.

Overview

Integrity signals

Registry

Crossref · 10.1002/ijc.33213

Cites

61 of 61 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Show all 64 references

3 of the 64 references couldn’t be matched to a known paper.

Research works printed but not linked: 6

  1. Fang XW, 2020, Clinical characteristics and treatment analysis of 79 patients infected with SARS‐CoV‐2, Chin Pharmacol Bull, 36, 453
  2. Li D, 2020, Clinical characteristics of 80 patients with COVID‐19 in Zhozhou city, Chin J Infect Control, 19, 227
  3. Li YL, 2020, Comparative study for clinical features between COVID‐19 patients with conventional type and heavy/critical type, Pract J Cardiac Cereb Pneumal Vasc Dis, 28, 14
  4. Sun DF, 2020, Clinical analysis of 30 patients infected with SARS‐CoV‐2, Zhejiang Clin Med, 22, 354
  5. Wang F, 2020, Clinical characteristics of 29 patients with COVID‐19 in Ningxia city, Ningxia Med J, 42, 263
  6. Tuo JY, 2016, Cancer incidence and mortality in cancer registries in Hubei Province, 2012, Cancer Res Prev Treat, 43, 974

Cited by

Sorted by citations

Items 101–128 of 128

Metadata

Authors
Tian, Y., Qiu, X., Wang, C., Zhao, J., Jiang, X., Niu, W., Huang, J., & Zhang, F.
Affiliations
  • Beijing University of Chinese Medicine (CN)
  • China-Japan Friendship Hospital (CN)
  • Peking University (CN)
Corresponding author
  • Niu, Wenquan
  • Huang, Jinchang
  • Zhang, Fengyu
Venue
International Journal of Cancer
Publisher
Wiley
Published
2020-08-15
Volume
148
Issue
2
Pages
363-374
ISSN
  • 0020-7136 (ISSN-L)
  • 1097-0215
OpenAlex
W3042427819
Cited by
129
References
64
Citations by year
2026: 3 · 2025: 7 · 2024: 6 · 2023: 22 · 2022: 42 · 2021: 41 · 2020: 7
FWCI
3.01
Type
journal article
Language
en
Open access
Locations
  • International Journal of Cancer (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
National Natural Science Foundation of China (81573736)
Topics
  • Health Sciences › Medicine › Oncology › COVID-19 and healthcare impacts
  • Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
  • Physical Sciences › Mathematics › Modeling and Simulation › COVID-19 epidemiological studies
Keywords
COVID-19 pandemic, cancer comorbidity, disease severity, mortality, risk factors, Hubei Province, publication bias
MeSH terms
COVID-19, SARS-CoV-2, Humans, Neoplasms, Risk Factors, Severity of Illness Index, Comorbidity, Prevalence, Risk Assessment, Pandemics

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review